Drugs / TIVV-IB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03927131 Comparator | May 2021 → Oct 2023 | influenza | Butantan Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIVV-IB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927131 ↗ |
| Modality | Vaccine | “Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage” NCT03927131 ↗ |